Back Hepatitis B Hepatitis B Topics HBV Treatment

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

IDWeek 2013: Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice

Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the second IDWeek conference held recently in San Francisco. Entecavir appeared to have an edge with regard to hepatitis B "e" antigen (HBeAg) seroconversion, but this rose with time among people taking either drug.

alt

Read more:

IAS 2013: Many People Need Hepatitis B Treatment in the Gambia

About 8% of people tested through a community-based screening program in the Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

Read more:

Hepatitis B Treatment with Entecavir Lowers Risk of Liver Cancer

Long-term treatment with entecavir (Baraclude) significantly reduces the chances of developing hepatocellular carcinoma compared with no treatment, and appears to lower the risk more than an older drug, especially for the most at-risk patients, according to a report in the July 2013 issue of Hepatology.

alt

Read more:

DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?

Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.

alt

Read more: